目次
TABLE OF CONTENTS
1 EXECUTIVE SUMMARY
2 MARKET INTRODUCTION
2.1 SCOPE OF THE STUDY
2.2 RESEARCH OBJECTIVE
2.3 MARKET STRUCTURE
2.4 ASSUMPTIONS & LIMITATIONS
3 RESEARCH METHODOLOGY
3.1 DATA MINING
3.2 SECONDARY RESEARCH
3.3 PRIMARY RESEARCH
3.4 BREAKDOWN OF PRIMARY RESPONDENTS
3.5 FORECASTING TECHNIQUES
3.6 RESEARCH METHODOLOGY FOR MARKET SIZE ESTIMATION
3.6.1 BOTTOM-UP APPROACH
3.6.2 TOP-DOWN APPROACH
3.7 DATA TRIANGULATION
3.8 VALIDATION
4 MARKET DYNAMICS
4.1 OVERVIEW
4.2 DRIVERS
4.2.1 RISING ZOONOTIC AND CHRONIC DISEASES IN ANIMALS
4.2.2 INCREASING EMPHASIS ON ANIMAL HEALTHCARE AND VACCINATION
4.2.3 INCREASED CONSUMPTION OF ANIMAL-BASED PRODUCTS
4.3 RESTRAINT
4.3.1 STRINGENT REGULATORY GUIDELINESANDHIGH STORAGE COSTSASSOCIATED WITH ANIMAL VACCINES
4.4 OPPORTUNITY
4.4.1 RISING INVESTMENTS IN VETERINARY HOSPITALSTO IMPROVE ANIMAL HEALTH
5 MARKET FACTOR ANALYSIS
5.1 VALUE CHAIN ANALYSIS
5.1.1 RESEARCH & DEVELOPMENT
5.1.2 MANUFACTURING
5.1.3 DISTRIBUTION AND SALES
5.1.4 POST-SALES MONITORING
5.2 PORTER'S FIVE FORCES MODEL
5.2.1 BARGAINING POWER OF SUPPLIERS
5.2.2 BARGAINING POWER OF BUYERS
5.2.3 THREAT OF NEW ENTRANTS
5.2.4 THREAT OF SUBSTITUTES
5.2.5 INTENSITY OF RIVALRY
5.3 IMPACT OF COVID-19ON THE GLOBAL ANIMAL VACCINES MARKET
5.3.1 IMPACT ON SUPPLY CHAIN
5.3.2 IMPACT OF COVID-19 ON ANIMAL DISEASE PREVENTION & CONTROL
5.3.3 IMPACT ON MARKET
6 GLOBAL ANIMAL VACCINES MARKET, BY TYPE
6.1 OVERVIEW
6.2 PORCINE VACCINES
6.3 POULTRY VACCINES
6.4 LIVESTOCK VACCINES
6.4.1 BOVINE VACCINES
6.4.2 SMALL RUMINANT VACCINES
6.5 COMPANION ANIMAL VACCINES
6.5.1 CANINE VACCINES
6.5.2 FELINE VACCINES
6.5.3 OTHERS
6.6 AQUACULTUTRE VACCINES
7 GLOBAL ANIMAL VACCINES MARKET, BY TECHNOLOGY
7.1 OVERVIEW
7.2 LIVE ATTENUATED VACCINES
7.3 INACTIVATED VACCINES
7.4 TOXOID VACCINES
7.5 RECOMBINANT VACCINES
7.6 OTHERS
8 GLOBAL ANIMAL VACCINES MARKET, BY REGION
8.1 OVERVIEW
8.2 AMERICAS
8.2.1 NORTH AMERICA
8.2.1.1 US
8.2.1.2 CANADA
8.2.2 SOUTH AMERICA
8.3 EUROPE
8.3.1 WESTERN EUROPE
8.3.1.1 FRANCE
8.3.1.2 GERMANY
8.3.1.3 UK
8.3.1.4 SPAIN
8.3.1.5 ITALY
8.3.1.6 REST OF WESTERN EUROPE
8.3.2 EASTERN EUROPE
8.4 ASIA-PACIFIC
8.4.1 JAPAN
8.4.2 CHINA
8.4.3 INDIA
8.4.4 AUSTRALIA
8.4.5 REPUBLIC OF KOREA
8.4.6 REST OF ASIA-PACIFIC
8.5 MIDDLE EAST & AFRICA
8.5.1 MIDDLE EAST
8.5.2 AFRICA
9 COMPETITIVE LANDSCAPE
9.1 COMPETITIVEOVERVIEW
9.2 MAJOR PLAYERS IN THE GLOBAL ANIMAL VACCINES MARKET
9.3 MAJOR GROWTH STRATEGIES IN THE GLOBAL ANIMAL VACCINES MARKET
9.4 COMPETITIVE BENCHMARKING
9.5 LEADING PLAYERS IN TERMS OF NUMBER OF DEVELOPMENTS IN THE GLOBAL ANIMAL VACCINES MARKET
9.6 KEY DEVELOPMENTS & GROWTH STRATEGIES
9.6.1 NEW PRODUCT DEVELOPMENTS/LAUNCHES
9.6.2 COLLABORATIONS/EXPANSIONS/PARTNERSHIPS/INVESTMENTS
9.7 MAJOR PLAYERS FINANCIAL MATRIX
9.7.1 REVENUE OF MAJOR PLAYERS, 2020
9.7.2 R&D EXPENDITURE, 2020
10 COMPANY PROFILES
10.1 BOEHRINGER INGELHEIM INTERNATIONAL GMBH
10.1.1 COMPANY OVERVIEW
10.1.2 FINANCIAL OVERVIEW
10.1.3 PRODUCTS OFFERED
10.1.4 KEY DEVELOPMENTS
10.1.5 SWOT ANALYSIS
10.1.6 KEY STRATEGIES
10.2 ZOETIS INC.
10.2.1 COMPANY OVERVIEW
10.2.2 FINANCIAL OVERVIEW
10.2.3 PRODUCTS OFFERED
10.2.4 KEY DEVELOPMENTS.
10.2.5 SWOT ANALYSIS
10.2.6 KEY STRATEGIES
10.3 CEVA SANTÉ ANIMALE
10.3.1 COMPANY OVERVIEW
10.3.2 FINANCIAL OVERVIEW
10.3.3 PRODUCTS/SERVICES OFFERED
10.3.4 KEY DEVELOPMENTS
10.3.5 KEY STRATEGIES
10.4 MERCK & CO., INC.
10.4.1 COMPANY OVERVIEW
10.4.2 FINANCIAL OVERVIEW
10.4.3 PRODUCTS OFFERED
10.4.4 KEY DEVELOPMENTS
10.4.5 SWOT ANALYSIS
10.4.6 KEY STRATEGIES
10.5 ELANCO ANIMAL HEALTH INCORPORATED
10.5.1 COMPANY OVERVIEW
10.5.2 FINANCIAL OVERVIEW
10.5.3 PRODUCTS OFFERED
10.5.4 KEY DEVELOPMENTS
10.5.5 SWOT ANALYSIS
10.5.6 KEY STRATEGIES
10.6 VIRBAC
10.6.1 COMPANY OVERVIEW
10.6.2 FINANCIAL OVERVIEW
10.6.3 PRODUCTS OFFERED
10.6.4 KEY DEVELOPMENTS
10.6.5 SWOT ANALYSIS
10.6.6 KEY STRATEGIES
10.7 PHIBRO ANIMAL HEALTH CORPORATION
10.7.1 COMPANY OVERVIEW
10.7.2 FINANCIAL OVERVIEW
10.7.3 PRODUCTS OFFERED
10.7.4 KEY DEVELOPMENTS
10.7.5 KEY STRATEGIES
10.8 HIPRA
10.8.1 COMPANY OVERVIEW
10.8.2 FINANCIAL OVERVIEW
10.8.3 PRODUCTS OFFERED
10.8.4 KEY DEVELOPMENTS
10.8.5 KEY STRATEGIES
10.9 BIOGÉNESIS BAGÓ S.A.
10.9.1 COMPANY OVERVIEW
10.9.2 FINANCIAL OVERVIEW
10.9.3 PRODUCTS OFFERED
10.9.4 KEY DEVELOPMENTS
10.9.5 KEY STRATEGIES
10.10 NEOGEN CORPORATION
10.10.1 COMPANY OVERVIEW
10.10.2 FINANCIAL OVERVIEW
10.10.3 PRODUCTS OFFERED
10.10.4 KEY DEVELOPMENTS
10.10.5 KEY STRATEGIES
11 APPENDIX
11.1 REFERENCES
11.2 RELATED REPORTS
